The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a ...
Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive pulmonary disease (COPD). It contains an inhaled corticosteroid called budesonide ...
The U.S. Food and Drug Administration said yesterday that it has given approval for the first generic of the Symbicort inhaler to treat asthma and COPD. Symbicort is a combination of budesonide and ...
The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...
Digital respiratory health company Propeller Health has received 510(k) clearance for a sensor and app intended for use with AstraZeneca's Symbicort inhaler for asthma and COPD, the company announced ...
Wilmington, DE – May 20, 2008 – A new 12-week study2examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT® (budesonide ...
Medpage Today on MSN
Triple Therapy Inhaler Improves Lung Function in Poorly Controlled Asthma
CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...
AstraZeneca PLCAZN announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone. Symbicort is presently marketed for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback